Just In
Program
Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quanterix Corp (NQ: QTRX )

12.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quanterix Corp

< Previous 1 2 3 4 5 6 7 Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
QTRX Investors Have Opportunity to Join Quanterix Corporation Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Earnings Scheduled For November 12, 2024
Via Benzinga
What's Next: Quanterix's Earnings Preview
Via Benzinga
Quanterix Corp. (NASDAQ: QTRX) Highlighted for Surprising Price Action
Via Investor Brand Network
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024
From Quanterix
Via Business Wire
Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024
From Quanterix Corporation
Via Business Wire
Earnings Preview: Quanterix
Via Benzinga
New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information
From Quanterix
Via Business Wire
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors
From Quanterix Corporation
Via Business Wire
Quanterix Announces Commercialization of p-Tau 217 Test Kit
From Quanterix Corporation
Via Business Wire
Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Jeffrey Elliott Appointed to Quanterix’s Board of Directors
From Quanterix Corporation
Via Business Wire
QTRX Stock Earnings: Quanterix Beats EPS, Beats Revenue for Q2 2024
QTRX stock results show that Quanterix beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Quanterix Releases Financial Results for the Second Quarter of 2024
From Quanterix Corporation
Via Business Wire
Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference
From Quanterix Corporation
Via Business Wire
Quanterix To Report Second Quarter 2024 Financial Results
From Quanterix Corporation
Via Business Wire
Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217
From Quanterix Corporation
Via Business Wire
Quanterix to Participate at the Scotiabank Healthcare 1x1 Day
From Quanterix Corporation
Via Business Wire
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
From Quanterix Corporation
Via Business Wire
QTRX Stock Earnings: Quanterix Beats EPS, Beats Revenue for Q1 2024
QTRX stock results show that Quanterix beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Quanterix Releases Financial Results for the First Quarter of 2024
From Quanterix Corporation
Via Business Wire
Quanterix To Report First Quarter 2024 Financial Results
From Quanterix Corporation
Via Business Wire
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
From Quanterix
Via Business Wire
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
From Quanterix Corporation
Via Business Wire
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
From Quanterix Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.